SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Sutton Lesley Ann)
 

Sökning: WFRF:(Sutton Lesley Ann) > Tailored approaches...

  • Baliakas, Panagiotis,1977-Uppsala universitet,Uppsala University,Science for Life Laboratory, SciLifeLab,Experimentell och klinisk onkologi (författare)

Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • 2018-09-27
  • Ferrata Storti Foundation (Haematologica),2019
  • 10 s.

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:5d2077f0-1ddb-4387-bedd-5d50b87c515f
  • https://lup.lub.lu.se/record/5d2077f0-1ddb-4387-bedd-5d50b87c515fURI
  • https://doi.org/10.3324/haematol.2018.195032DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-377215URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:140220481URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-516759URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Chronic lymphocytic leukemia (CLL) patients with differential somatic hypermutation status of the immunoglobulin heavy variable genes, namely mutated or unmutated, display fundamental clinico-biological differences. Considering this, we assessed prognosis separately within mutated (M-CLL) and unmutated (U-CLL) CLL in 3015 patients, hypothesizing that the relative significance of relevant indicators may differ between these two categories. Within Binet A M-CLL patients, besides TP53 abnormalities, trisomy 12 and stereotyped subset #2 membership were equivalently associated with the shortest time-to-first-treatment and a treatment probability at five and ten years after diagnosis of 40% and 55%, respectively; the remaining cases exhibited 5-year and 10-year treatment probability of 12% and 25%, respectively. Within Binet A U-CLL patients, besides TP53 abnormalities, del(11q) and/or SF3B1 mutations were associated with the shortest time-to-first-treatment (5- and 10-year treatment probability: 78% and 98%, respectively); in the remaining cases, males had a significantly worse prognosis than females. In conclusion, the relative weight of indicators that can accurately risk stratify early-stage CLL patients differs depending on the somatic hypermutation status of the immunoglobulin heavy variable genes of each patient. This finding highlights the fact that compartmentalized approaches based on immunogenetic features are necessary to refine and tailor prognostication in CLL.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Moysiadis, TheodorosCenter for Research and Technology Hellas,Ctr Res & Technol Hellas, Inst Appl Biosci, Thessaloniki, Greece (författare)
  • Hadzidimitriou, AnastasiaUppsala universitet,Uppsala University,Center for Research and Technology Hellas,Experimentell och klinisk onkologi,Science for Life Laboratory, SciLifeLab,Ctr Res & Technol Hellas, Inst Appl Biosci, Thessaloniki, Greece (författare)
  • Xochelli, AlikiUppsala universitet,Uppsala University,Center for Research and Technology Hellas,Experimentell och klinisk onkologi,Science for Life Laboratory, SciLifeLab,Ctr Res & Technol Hellas, Inst Appl Biosci, Thessaloniki, Greece(Swepub:uu)alixo978 (författare)
  • Jeromin, SabineMunich Leukemia Laboratory (MLL),MLL Munich Leukemia Lab, Munich, Germany (författare)
  • Agathangelidis, AndreasKarolinska Institutet,Center for Research and Technology Hellas (författare)
  • Mattsson, MattiasUppsala universitet,Uppsala University,Experimentell och klinisk onkologi,Science for Life Laboratory, SciLifeLab(Swepub:uu)matma431 (författare)
  • Sutton, Lesley AnnUppsala universitet,Uppsala University,Science for Life Laboratory, SciLifeLab,Experimentell och klinisk onkologi(Swepub:uu)lessu455 (författare)
  • Minga, EvaCenter for Research and Technology Hellas,Ctr Res & Technol Hellas, Inst Appl Biosci, Thessaloniki, Greece (författare)
  • Scarfò, LydiaVita-Salute San Raffaele University,San Raffaele Scientific Institute,IRCCS Ist Sci San Raffaele, Div Expt Oncol, Milan, Italy;Univ Vita Salute San Raffaele, Milan, Italy (författare)
  • Rossi, DavideOncology Institute of Southern Switzerland,Oncol Inst Southern Switzerland, Bellinzona, Switzerland (författare)
  • Davis, ZadieRoyal Bournemouth Hospital,Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England (författare)
  • Villamor, NeusHospital Clínic of Barcelona,Hosp Clin Barcelona, Hemopathol Unit, Barcelona, Spain (författare)
  • Parker, HelenUniversity of Southampton,Univ Southampton, Canc Res UK Ctr, Acad Unit Canc Sci, Canc Genon, Southampton, Hants, England;Univ Southampton, Fac Med, Expt Canc Med Ctr, Southampton, Hants, England (författare)
  • Kotaskova, JanaMasaryk University,University Hospital Brno,Masaryk Univ, Cent European Inst Technol, Brno, Czech Republic;Univ Hosp Brno, Brno, Czech Republic (författare)
  • Stalika, EvangeliaGeorge Papanicolaou General Hospital,Center for Research and Technology Hellas,Ctr Res & Technol Hellas, Inst Appl Biosci, Thessaloniki, Greece;G Papanicolaou Hosp, Hematol Dept, Thessaloniki, Greece;G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece (författare)
  • Plevova, KarlaUniversity Hospital Brno,Masaryk University,Masaryk Univ, Cent European Inst Technol, Brno, Czech Republic;Univ Hosp Brno, Brno, Czech Republic (författare)
  • Mansouri, LarryKarolinska Institutet,Uppsala universitet,Uppsala University,Science for Life Laboratory, SciLifeLab,Experimentell och klinisk onkologi(Swepub:uu)maman377 (författare)
  • Cortese, DiegoUppsala universitet,Uppsala University,Science for Life Laboratory, SciLifeLab,Experimentell och klinisk onkologi(Swepub:uu)dieco231 (författare)
  • Navarro, AlbaHospital Clínic of Barcelona,Hosp Clin Barcelona, Hemopathol Unit, Barcelona, Spain (författare)
  • Delgado, JulioHospital Clínic of Barcelona,Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain (författare)
  • Larrayoz, MartaUniversity of Southampton,Univ Southampton, Canc Res UK Ctr, Acad Unit Canc Sci, Canc Genon, Southampton, Hants, England;Univ Southampton, Fac Med, Expt Canc Med Ctr, Southampton, Hants, England (författare)
  • Young, EmmaUppsala universitet,Uppsala University,Science for Life Laboratory, SciLifeLab,Experimentell och klinisk onkologi(Swepub:uu)emmyo327 (författare)
  • Anagnostopoulos, AchillesGeorge Papanicolaou General Hospital,G Papanicolaou Hosp, Hematol Dept, Thessaloniki, Greece;G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece (författare)
  • Smedby, Karin E.Karolinska Institutet,Karolinska Institute,Karolinska Inst, Clin Epidemiol Unit, Dept Med, Stockholm, Sweden (författare)
  • Juliusson, GunnarLund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital,Lund Univ & Hosp, Lund Stem Cell Ctr, Dept Hematol, Lund, Sweden(Swepub:lu)stem-gju (författare)
  • Sheehy, OonaghBelfast City Hospital,Belfast City Hosp, Dept Hematooncol, Belfast, Antrim, North Ireland (författare)
  • Catherwood, MarkBelfast City Hospital,Belfast City Hosp, Dept Hematooncol, Belfast, Antrim, North Ireland (författare)
  • Strefford, Jonathan C.University of Southampton,Univ Southampton, Canc Res UK Ctr, Acad Unit Canc Sci, Canc Genon, Southampton, Hants, England;Univ Southampton, Fac Med, Expt Canc Med Ctr, Southampton, Hants, England (författare)
  • Stavroyianni, NikiGeorge Papanicolaou General Hospital,G Papanicolaou Hosp, Hematol Dept, Thessaloniki, Greece;G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece (författare)
  • Belessi, ChrysoulaNikea General Hospital, Piraeus,Nikea Gen Hosp, Hematol Dept, Piraeus, Greece (författare)
  • Pospisilova, SarkaMasaryk University,University Hospital Brno,Masaryk Univ, Cent European Inst Technol, Brno, Czech Republic;Univ Hosp Brno, Brno, Czech Republic (författare)
  • Oscier, DavidRoyal Bournemouth Hospital,Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England (författare)
  • Gaidano, GianlucaUniversity of Eastern Piedmont,Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, Novara, Italy (författare)
  • Campo, EliasUniversity of Barcelona,Hospital Clínic of Barcelona,Hosp Clin Barcelona, Hemopathol Unit, Barcelona, Spain;Univ Barcelona, Dept Pathol, Barcelona, Spain (författare)
  • Haferlach, ClaudiaMunich Leukemia Laboratory (MLL),MLL Munich Leukemia Lab, Munich, Germany (författare)
  • Ghia, PaoloVita-Salute San Raffaele University,San Raffaele Scientific Institute,IRCCS Ist Sci San Raffaele, Div Expt Oncol, Milan, Italy;Univ Vita Salute San Raffaele, Milan, Italy (författare)
  • Rosenquist, RichardKarolinska Institutet,Karolinska Institute,Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden (författare)
  • Stamatopoulos, KostasUppsala University,Center for Research and Technology Hellas,Karolinska Inst, Clin Epidemiol Unit, Dept Med, Stockholm, Sweden (författare)
  • Uppsala UniversityScience for Life Laboratory, SciLifeLab (creator_code:org_t)
  • European Research Initiative on CLL (ERIC)

Sammanhörande titlar

  • Ingår i:Haematologica: Ferrata Storti Foundation (Haematologica)104:2, s. 360-3691592-87210390-6078

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy